Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

India to start building 20 km roads per day by April: Nath
Road Transport and Highways Minister Kamal Nath said here that India had increased its per-day construction of roads to 9 km and the target of developing 20 km daily would be accomplished by April.“We have reached 9 km per day of road construction and will hit our target of 20 km a day by April,” Nath, who was here to hold talks with the Malaysian government to invite them to enter the highway construction sector in India, said.Thirty-five Malaysian companies are already involved with various infrastructure projects in India.To construct 20 km of raods a day or 7,000 km a year, there had to be 20,000 km of work in progress, he said.

T N Ninan: Hold fast
T N Ninan / New Delhi October 31, 2009, 1:07 IST

News of the day

Protectionism by another name
Business Standard / New Delhi November 18, 2009, 0:15 IST
Business Ideas

Glenmark Pharma Q2 net dips 31% to Rs 81 cr

Drug maker Glenmark Pharmaceuticals today reported 31 per cent drop in its consolidated net profit at Rs 80.88 crore for the second quarter ended September 2009. - Aurobindo gets SA regulator"s nod to market drugs - Glenmark Generics files IPO prospectus with Sebi - Glenmark raises Rs 413 cr in QIP - Natco to make 10 mn strips of generic Tamiflu available by Oct - Glenmark plans to raise Rs 300-350 cr through QIP - Glenmark"s drug fails clinical trials Total income rose to Rs 616.56 crore during the quarter from Rs 604.21 crore against the year-ago period, Glenmark said in a filing to the Bombay Stock Exchange (BSE). "Sales growth across most regions for the quarter has improved. The India formulations business and the US generics business performed well during the quarter," Glenmark Pharma CEO & MD Glenn Saldanha said. The company"s sales from formulations business in India increased 18 per cent to Rs 184.26 crore, while the revenue from the US generics business rose to Rs 177.11 crore from Rs 176.13 crore in the same period last fiscal. "For the remaining part of the year, we expect demand conditions to further improve across all our operating regions. While the US Generics and the India formulations business should continue to grow, the remaining regions are also expected to register good growth rates," Saldanha added. During the period, Glenmark"s revenue from Africa, Asia and CIS (Commonwealth of Independent States) grew 14 per cent to Rs 80.22 crore. On a stand alone basis, Glenmark Pharma posted a net profit of Rs 57.50 crore for the September quarter, a 14.03 per cent drop over the year-ago period. Shares of Glenmark Pharma were trading at Rs 220, down 0.18 per cent over previous close on the BSE.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009